300357 Share Price | Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Positive results in Mar 25

RAW MATERIAL COST(Y) Fallen by -4.57% (YoY)
CASH AND EQV(HY) Highest at CNY 2,601.1 MM
DEBTORS TURNOVER RATIO(HY) Highest at 3.93%

With ROE of 13.33%, it has a expensive valuation with a 5.21 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 13,375 Million (Large Cap)

P/E

39.00

Industry P/E

Dividend Yield

0.86%

Debt Equity

-0.51

Return on Equity

14.15%

Price to Book

5.07

Revenue and Profits:

Net Sales:

369 Million

(Quarterly Results - Sep 2025)

Net Profit:

165 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.54%

6 Months

9.44%

1 Year

39.11%

2 Years

18.93%

3 Years

-49.02%

4 Years

-39.84%

5 Years

-68.96%

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Reports Mixed Financial Results Amid Market Challenges

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a prominent player in the pharmaceuticals and biotechnology sector, has recently reported its financial performance for the quarter ending March 2025. The results indicate a challenging period for the company, marked by negative financial outcomes.

Despite the overall downturn, there are some noteworthy highlights in the financial metrics. The company experienced a significant decrease in raw material costs, which fell by 4.57% year-over-year. This reduction may provide some relief in terms of operational expenses, potentially aiding in future profitability.

Furthermore, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. reported its highest cash and equivalents position at CNY 2,601.1 MM. This strong liquidity position could offer the company flexibility in managing its operations and pursuing growth opportunities, e...

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.35%

EBIT Growth (5y)

3.92%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.53

Sales to Capital Employed (avg)

0.39

Tax Ratio

16.34%

Dividend Payout Ratio

36.24%

Pledged Shares

Institutional Holding

ROCE (avg)

38.77%

ROE (avg)

15.88%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.21

EV to EBIT

32.84

EV to EBITDA

28.42

EV to Capital Employed

10.31

EV to Sales

11.85

PEG Ratio

3.50

Dividend Yield

0.90%

ROCE (Latest)

31.40%

ROE (Latest)

13.33%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 22.62% vs 4.70% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 37.45% vs 1.52% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "369.10",
          "val2": "301.00",
          "chgp": "22.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "186.80",
          "val2": "143.00",
          "chgp": "30.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "-0.80",
          "chgp": "137.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "164.80",
          "val2": "119.90",
          "chgp": "37.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "506.00%",
          "val2": "429.80%",
          "chgp": "7.62%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.11% vs -5.33% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.98% vs -11.97% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "922.30",
          "val2": "845.30",
          "chgp": "9.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "368.50",
          "val2": "345.10",
          "chgp": "6.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.50",
          "chgp": "-13.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.00",
          "val2": "-1.20",
          "chgp": "183.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "304.30",
          "val2": "295.50",
          "chgp": "2.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "342.00%",
          "val2": "361.60%",
          "chgp": "-1.96%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

369.10

301.00

22.62%

Operating Profit (PBDIT) excl Other Income

186.80

143.00

30.63%

Interest

0.20

0.30

-33.33%

Exceptional Items

0.30

-0.80

137.50%

Consolidate Net Profit

164.80

119.90

37.45%

Operating Profit Margin (Excl OI)

506.00%

429.80%

7.62%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 22.62% vs 4.70% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 37.45% vs 1.52% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

922.30

845.30

9.11%

Operating Profit (PBDIT) excl Other Income

368.50

345.10

6.78%

Interest

1.30

1.50

-13.33%

Exceptional Items

1.00

-1.20

183.33%

Consolidate Net Profit

304.30

295.50

2.98%

Operating Profit Margin (Excl OI)

342.00%

361.60%

-1.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 9.11% vs -5.33% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 2.98% vs -11.97% in Dec 2023

All Annual Results

Company CV

About Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available